^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular Predictors of Outcome With Gefitinib and Docetaxel in Previously Treated Non–Small-Cell Lung Cancer: Data From the Randomized Phase III INTEREST Trial
Excerpt:
Response rates associated with KRAS mutations versus wild-type were 0% (0 of 20) versus 9.6% (nine of 94) for gefitinib and 3.7% (one of 27) versus 11.9% (13 of 109) for docetaxel...
Secondary therapy:
docetaxel
DOI:
10.1200/JCO.2009.24.3030
Trial ID:
Source:
Title:
Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand
Excerpt:
...Time to maximum response`Overall survival`Prevalence of EGFR & KRAS mutation from laboratory result...
Trial ID:
Source:
Title:
Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis
Published date:
03/24/2022
Excerpt:
...we explored the antitumor ability of gefitinib in combination with betulin to overcome drug resistance through ferroptosis in wild-type EGFR/KRAS-mutant NSCLC cells….A xenograft model was constructed in vivo to investigate the role of the combination treatment of betulin and gefitinib in NSCLC tumor growth. Gefitinib in combination with betulin exhibited antagonistic effects on cellular viability and induced cell apoptosis...it also inhibited the tumor growth of NSCLC in vivo. Our findings suggest that gefitinib in combination with betulin is a novel therapeutic approach to overcome gefitinib resistance in EGFR wild-type/KRAS-mutant NSCLC cells by inducing ferroptosis.
DOI:
10.4149/neo_2022_211103N1568
Source:
Title:
TP53 mutation influences the efficacy of treatment of colorectal cancer cell lines with a combination of sirtuin inhibitors and chemotherapeutic agents
Published date:
05/29/2020
Excerpt:
The HCT116 (KRASmut and TP53wt) and SW620 (KRASmut and TP53mut) cells were treated with NAM (a broad spectrum SIRT inhibitor), EX527 (a SIRT1 inhibitor) or AGK2 (a SIRT2 inhibitor) and the respective IC50 values were calculated (Fig. 1). Similarly, the IC50 values of cisplatin, 5-FU, irinotecan, oxaliplatin, paclitaxel, EGFR inhibitor gefitinib, PI3K inhibitor LY294002, pyruvate dehydrogenase kinase inhibitor DCA and the gluconeogenesis inhibitor metformin were determined (Fig. 2). These findings suggested that, SIRT inhibitors and chemotherapeutic agents had tumor inhibitory effects on CRCs.
DOI:
10.3892/etm.2020.8818
Source:
Title:
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines
Excerpt:
CONTRADICTING EVIDENCE: We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines….IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay….Multivariate analyses led to the following results: 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance. 2. mKRAS was associated with increased in vitro resistance to gefitinib....
DOI:
10.1371/journal.pone.0004576
